CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX) have been given an average recommendation of “Moderate Buy” by the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $12.9444.

Several brokerages have recently weighed in on CYRX. Wall Street Zen downgraded CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Finally, Needham & Company LLC increased their target price on CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th.

Insider Transactions at CryoPort

In other CryoPort news, CEO Jerrell Shelton sold 7,918 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the transaction, the chief executive officer directly owned 1,054,501 shares in the company, valued at $8,436,008. This represents a 0.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark W. Sawicki sold 3,235 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $25,880.00. Following the transaction, the insider directly owned 103,697 shares in the company, valued at approximately $829,576. This trade represents a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 54,610 shares of company stock worth $427,592. Insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Basepoint Wealth LLC bought a new stake in CryoPort during the 4th quarter valued at $34,000. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of CryoPort during the third quarter valued at $53,000. Tower Research Capital LLC TRC increased its stake in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after buying an additional 4,375 shares during the period. AlphaQuest LLC bought a new stake in shares of CryoPort in the third quarter valued at about $79,000. Finally, ProShare Advisors LLC bought a new stake in shares of CryoPort in the second quarter valued at about $75,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Trading Down 3.0%

Shares of NASDAQ:CYRX opened at $8.04 on Monday. CryoPort has a 12 month low of $4.63 and a 12 month high of $11.45. The company has a market capitalization of $400.87 million, a price-to-earnings ratio of 6.09 and a beta of 1.69. The firm’s 50-day moving average is $9.05 and its 200 day moving average is $9.35.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $42.92 million. As a group, equities analysts forecast that CryoPort will post -0.99 EPS for the current fiscal year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.